Cover Image
市場調查報告書

第二型糖尿病:EU5個國家的市場障礙分析

FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (EU5)

出版商 FirstWord 商品編碼 330354
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
第二型糖尿病:EU5個國家的市場障礙分析 FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (EU5)
出版日期: 2015年04月20日 內容資訊: 英文
簡介

本報告提供EU5個國家的第二型糖尿病的治療藥市場相關調查分析、市場障礙 (產品價格、有效性、償付情形) 的影響、治療藥的市場佔有率、障礙造成影響的比例等相關的系統性資訊。

目前用戶基礎和整體市場障礙的影響

  • 目前使用概況 和顧慮事項
  • 整體市場障礙的影響
  • 障礙造成的損益
  • 障礙效果的評估法

品牌固有的障礙的影響

  • 市場佔有率增減的理由
  • 市場佔有率增加
  • 市場佔有率減少

附錄

  • 醫療專家簡介
  • 障礙效果的評估法:摘要
目錄
Product Code: 596200399

What market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (EU5) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (US) .

Based on data gained from proprietary analytics, gain visibility into why physicians are prescribing, or not, certain drugs to treat T2DM. This information allows you to act strategically, drive market share gains and improve competitiveness for your brand.

Get Answers to Key Questions

  • How does product pricing, availability and reimbursement affect a physician's decision to prescribe one product over another?
  • What T2DM drug treatments are gaining share and which ones are losing share due to these barriers?
  • In the T2DM market, what percentage of prescriptions are influenced by barriers, what are the barriers experienced and the volume of prescriptions these barriers represent?

Insight and Analysis Provided

  • AstraZeneca
    • Byetta (exenatide)
    • Onglyza (saxagliptin)
    • Farxiga (dapagliflozin)
  • Johnson & Johnson
    • Invokana (canagliflozin)
  • Merck & Co.
    • Januvia (sitagliptin)
  • Novo Nordisk
    • Victoza (liraglutide)
    • Levemir (Insulin detemir)
  • Sanofi
    • Lantus (Insulin glargine)

Key Issues Explored

  • The amount of share your brand gains and loses due to specific market barriers.
  • The user mix for your brand, plus doctors who are not current users but would consider using it.
  • The percentage of prescriptions influenced by barriers, the barriers experienced and the volume of scripts these barriers represent.

Table of Contents

Current user base and overall market barrier impact

  • Current usage and consideration
  • Overall market barrier impact
  • Losses and gains due to barriers
  • Barrier effect score

Brand specific barrier impact

  • Why do I lose or gain share?
  • Who gets my share?
  • Whose share do I get?

Appendix

  • Physician profile
  • Barrier effect score summary
Back to Top